In a retrospective study 37 patients who fitted into the clinical spectrum of myelodysplastic syndrome were reviewed. Special attention was paid to the influence of monocyte count, degree of blastic infiltration and ring sideroblasts and on the clinical presentation and the course of the disease. Monocyte count clearly distinguishes between two groups of patients with different haematological profile and clinical course. The patients with monocytosis frequently changed to acute myeloid leukaemia and had shorter survival rates compared with those without monocytosis. The degree of blastic infiltration does not affect the haematological presentation and the frequency of acute leukaemia evolution. However, increased blastic infiltration is associated with shorter survival. Patients with ringed sideroblasts presented with profound anaemia but the clinical course of the disease did not differ from the remainder.

Keywords:
Blastic infiltration, Monocyte count, Myelodysplastic syndrome, Prognosis, Sideroblasts
This content is only available via PDF.
© 1981 S. Karger AG, Basel
1981
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.